Kenalog

Triamcinolone Acetonide, the active ingredient in Kenalog, is a corticosteroid presented as a sterile injectable for intra‑articular and intramuscular use. It is employed to reduce inflammation and immune responses in musculoskeletal and dermatologic conditions, and is prescribed for adult patients requiring localized or systemic glucocorticoid therapy.

GNH USA supplies Kenalog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics. Our portfolio includes a range of injectable medicines for diverse therapeutic areas.

Kenalog (triamcinolone acetonide) is a corticosteroid used to manage inflammatory and immune‑mediated conditions affecting joints, skin, and allergic responses.

- Rheumatoid arthritis (intra‑articular): reduces joint swelling, pain, and stiffness. - Osteoarthritis (intra‑articular): alleviates pain and improves joint function. - Psoriasis (intralesional): decreases plaque thickness and erythema. - Severe allergic reactions (intramuscular): suppresses systemic hypersensitivity and reduces edema.

Kenalog may cause a range of adverse reactions, most of which are related to its glucocorticoid activity.

Common Side Effects: - Pain or irritation at the injection site. - Transient hyperglycemia, especially in diabetic patients. - Mild skin thinning or bruising. - Headache or dizziness. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Adrenal suppression or insufficiency. - Severe infection or sepsis. - Vision changes, including cataracts or glaucoma. - Anaphylactic or severe allergic reaction. - Cushingoid appearance with prolonged use. - Osteonecrosis of the jaw or other bones.

Before initiating Kenalog therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

- Infection risk: screen for active infections and avoid use in systemic fungal disease. - Glycemic control: monitor blood glucose in diabetic patients. - Bone health: assess osteoporosis risk, especially with repeated intra‑articular injections. - Cardiovascular: use caution in patients with hypertension or fluid retention. - Pregnancy and lactation: consider risk‑benefit ratio due to limited safety data. - Store below 25°C: keep in the original container, protect from moisture and light.

Kenalog can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors (e.g., ketoconazole) may increase corticosteroid exposure. - Live vaccines: risk of vaccine‑derived infection. - Systemic anticoagulants: heightened bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased gastrointestinal ulceration. - Other immunosuppressants: additive immunosuppression.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate fluid retention and electrolyte imbalance. - Antidiabetic agents: monitor for hyperglycemia. - Antihypertensives: possible reduction in blood‑pressure control. - Anticholinergic drugs: may enhance dry‑mouth effects. - Herbal supplements (e.g., St. John’s wort): may affect steroid metabolism.